Home Politics Religion Media Biz Society Tech Travel Books Intl. Autos Automobiles
                        Aviation   Pharma   About Us   Feedback   Links
PHARMA - NOVARTIS ACQUIRES BRISTOL-MYERS OTC

Novartis acquires Bristol-Myers’ OTC business in US

 

BY OUR PHARMA  CORRESPONDENT

20 July, 2005: In an effort to bolster its position in the growing over-the-counter (OTC) marketplace, Swiss drugs group Novartis has agreed to acquire Bristol-Myers Squibb's US portfolio for $660m (£379m).

BMS' OTC unit registered sales of $258m last year.Novartis currently ranks as the number two OTC firm in Europe.

Analysts have described the cash deal, which will see Novartis pay 2.6 times sales, as a fair price for the BMS' North American OTC portfolio as it allows to strengthen its hold on the US marketplace and broaden its therapeutic range.

The acquisition will help Novartis enter into $2 billion worth US adult analgesic marketplace with Excedrin, a $160m-earning pain killer. The drug, a triple combination of paracetamol, aspirin and caffeine, is the number two product in the area, with 96 per cent consumer awareness, according to Novartis.

Other brands in the BMS portfolio include Keri, a skin care product, Comtrex, for cold and flu, Vagistat, an anti-fungal, 4-Way, a nasal decongestant, Mineral Ice, a topical pain reliever, No-Doz, a sleep medicine, and Bufferin, a systemic analgesic.

Apart form providing the critical mass in the OTC market, the acquisition would boost the attractiveness of Novartis Consumer Health as a partner for switching prescription medicines to OTC status. 

Analysts also noted that the deal made excellent synergy with Novartis' existing OTC product range, complementing the portfolio already sold by the company in North America.

News of Novartis' BMS came hot on the heels of a positive announcement from the company that sales and profits had exceeded expectation in the first half 2005.

 

MORE CORPORATE NEWS
Deals and pacts, mergers and acquisitions, lawsuits etc

Second trial on Merck’s painkiller Vioxx begins
17 September, 2005

Impax delisted from Nasdaq

39 drug firms sued over price rigging in California

Chiron rebuffs Novartis' bid

Nasdaq delists Able on bankruptcy filing

Some of the Vioxx suits may be settled: Merck

Glaxo Smithkline in pact with IAVI to develop AIDS drug

Pfizer acquires Vicuron Pharma for $1.9 billion

Ranbaxy acquires generic product portfolio from Efarmes

Novasite Pharma buys PsyCheNomicS

Temasek sets up $112 million pharma JV

Able Laboratories files bankruptcy suit with US court

Cardiac Science-Defibtech lawsuit settled

Par loses ondansetron case to GSK

Florida sues Mylan, Teva and Watson

Lupin in pact with Kyowa of Japan

British Pharma seeks opinion on industry code

European biotech start-ups fail to win late-stage funds

Afghan’s first generics plant to go on stream by Oct. ‘05

Merck sets up generic arm Genpharm in US

Novo Nordisk, Eli Lilly remove insulin products from Australia

Glaxo inks co-promotion pact with Eisai for Paritec

Elder Pharma plans unit, brand acquisition

Nectar Lifesciences plans Rs 90 crore IPO

Genepharm in pact with 3 Australian distributors 

Novartis acquires Bristol-Myers’ OTC business in US

Novartis completes Eon Labs buy

Orbus inks supply pact with Docpharma 

Novartis acquires rights of kidney dialysis drug from SeBo

Nektar buys out Aerogen for $32 m

BioVeris licenses Baxter's vaccine portfolio

Carl Icahn sells Mylan shares

Dey and Connecticut settle pricing dispute

   Pharma Home

 

Home Politics Religion Media Biz Society Tech Travel Books Intl. Autos Automobiles
                        Aviation   Pharma   About Us   Feedback   Links

Latest updates    Contact Us - Feedback    About Us